2017-05-11
To the editor: Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Publication
Publication
Blood , Volume 129 - Issue 19 p. 2702- 2705
| Additional Metadata | |
|---|---|
| doi.org/10.1182/blood-2017-01-761973, hdl.handle.net/1765/100107 | |
| Blood | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Fischer, K., Al-Sawaf, O. (Othman), Fink, A.-M. (Anna-Maria), Dixon, M. (Mark), Bahlo, J. (Jasmin), Warburton, S. (Simon), Kipps, T.J. (Thomas J.), Weinkove, R. (Robert), Robinson, S. (Sue), Seiler, T. (Till), Opat, S., Owen, C., López, J. (Javier), Humphrey, K., Humerickhouse, R., Tausch, E. (Eugen), Frenzel, L. (Lukas), Eichhorst, B., Wendtner, C. M., … Hallek, M. (2017). To the editor: Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 129(19), 2702–2705.https://doi.org/10.1182/blood-2017-01-761973 |
|